Drug Development and Screening Core

Drug options are determined through our Drug Development and Screening Core. Personalized medicine can provide valuable information guiding therapeutic decisions, bur for many changes happening at the DNA or protein level we do not yet have accepted treatment regimens. This core allows us to test many different drugs and to make our own unique drugs to stop individual cancers from growing.

Lead Investigators
  • Dr. John Trant, Chemistry & Biochemistry, University of Windsor
  • Dr. Simon Rondeau-Gagné, Chemistry & Biochemistry, University of Windsor
  • Dr. Huiming Zhang, Biological Sciences, University of Windsor
  • Dr. Lisa A. Porter, Biological Sciences, University of Windsor
  • Dr. Phillip Karpowicz, Biological Sciences, University of Windsor
Equipment Available Supported by
Zebrafish drug screening platform (developed in collaboration with Acenzia)
Zebrafish offer a unique advantage in that they have an intact immune system and provide an environment more representative of the human body to determine the effects of individual patient tumours. Patient cells are injected into fertilized eggs and grow to produce a tiny zebrafish containing a human tumour. we can rapidly screen many drugs to determine the best drug combination for each patients tumour. This screening platform was supported by Caesars Windsor.
 
Organoid screening platform

This is an animal free facility that uses patient-derived tumour tissue to establish ‘tumours in a dish’ that can be used to screen a host of drugs.

Core Needs
  • High throughput peptide synthesizer
  • LC-MS-MS GC-MS
  • Automated patch clamp system
  • Robot for automated sampling – reduces human error for large drug screens
  • Incucyte system to monitor organoid changes